|Description||ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patients in a proof-of-concept clinical trial. But Phase-II for Hepatitis C treatment was discontinued.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Achillion Pharmaceuticals|
Ledipasvir is an inhibitor of hepatitis C virus NS5A.
RO-9187 is a potent inhibitor of HCV virus replication in the replicon system. It is excellent substrates for deoxycytidine kinase and were phosphorylated with ...
GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex i...
Paritaprevir could inhibit viral phosphoprotein NS5A and is significant to viral replication and other activities. It also has been found to have potential effe...
PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.
Asunaprevir is a potent hepatitis C virus (HCV) non-structural protein protease inhibitor currently in Phase III clinical trials for the treatment of HCV infect...
2'-C-Methylcytidine, also called as NM107, inhibits the replication of HCV RNA and exerts inhibitory activity and cytotoxicity against HCV 1b replicon cells (IC...
Velpatasvir is a selective Hepatitis C virus NS 5 protein inhibitor originated by Gilead Sciences. It showed pan-genotypic activity and a high barrier to resist...